GlassScriptPhysician profile
Shannon E Lemp
NPI 1134725385
$2,311.96
in general payments reported to CMS, 2019-2025
30 companies · $41.07 in 2025
The $41.07 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,037 · 2022: $887 · 2023: $281 · 2024: $65.80 · 2025: $41.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $299.26 | 2021-2022 | |
| Novo Nordisk INC | $202.83 | 2021-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $195.23 | 2021-2023 | Rexulti |
| Amgen INC. | $156.27 | 2021-2023 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $135.62 | 2021-2023 | Shingrix |
| Lundbeck LLC | $92.40 | 2021-2023 | Rexulti |
| Abbott Laboratories | $86.93 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $82.96 | 2021-2022 | |
| Bausch Health US, LLC | $76.35 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $54.98 | 2022-2023 | Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $54.07 | 2021-2023 | Trintellix |
| Acerus Pharmaceuticals Corporation | $53.86 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.30 | 2022 | |
| Merck Sharp & Dohme LLC | $43.67 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $41.96 | 2021 | |
| Sanofi-Aventis U.S. LLC | $29.54 | 2022 | |
| Astellas Pharma US INC | $20.83 | 2021 | |
| Axsome Therapeutics, INC. | $20.01 | 2022 | |
| Lilly USA, LLC | $16.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.21 | 2021 | |
| Genentech USA, INC. | $15.97 | 2021 | |
| Esperion Therapeutics, INC. | $15.76 | 2021 | |
| Exact Sciences Corporation | $14.56 | 2023 | Cologuard Collection Kit |
| Acadia Pharmaceuticals INC | $14.40 | 2022 | |
| Seqirus USA INC | $13.85 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.64 | 2022 | |
| Adlon Therapeutics L.P. | $13.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Lemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.